<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728932</url>
  </required_header>
  <id_info>
    <org_study_id>P170914J</org_study_id>
    <secondary_id>2019-004319-29</secondary_id>
    <nct_id>NCT04728932</nct_id>
  </id_info>
  <brief_title>LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients</brief_title>
  <acronym>LEVOECMO</acronym>
  <official_title>LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last decade, venoarterial extracorporeal membrane oxygenation (VA-ECMO) has become the&#xD;
      first-line therapy in patients with refractory cardiogenic shock. VA-ECMO provides both&#xD;
      respiratory and cardiac support, is easy to insert, even at the bedside, provides stable flow&#xD;
      rates, and is associated with less organ failure after implantation compared to large&#xD;
      biventricular assist-devices that require open-heart surgery. In patients with potentially&#xD;
      reversible cardiac failure (e.g. myocarditis, myocardial stunning post-myocardial infarction,&#xD;
      post-cardiotomy or post-cardiac arrest), VA-ECMO might be weaned after a few days of support&#xD;
      and used as a bridge to recovery.&#xD;
&#xD;
      Although considered as the ultimate life-saving technology for refractory cardiac failure,&#xD;
      veno-arterial ECMO is still associated with severe complications. Specifically, excessive LV&#xD;
      afterload and lack of LV unloading under VA-ECMO might induce LV stasis with thrombus&#xD;
      formation, pulmonary edema, myocardial ischemia caused by ventricular distension and&#xD;
      ultimately increase mortality. ECMO support also exposes to many complications such as&#xD;
      infections, hemorrhage or peripheral vascular embolism. These complications are more frequent&#xD;
      with prolonged support and are responsible for significant morbidity and mortality, prolonged&#xD;
      ICU and hospital stays and higher costs.&#xD;
&#xD;
      Levosimendan, which acts to sensitize myocardial contractile proteins to calcium, improves&#xD;
      cardiac contractility without increasing the intracellular calcium concentration. Unlike&#xD;
      traditional inotropes such as dobutamine, levosimendan neither increases myocardial oxygen&#xD;
      consumption nor impairs diastolic function or possess proarrhythmic effects. It also&#xD;
      influences the opening of ATP-dependent potassium channels, including those in vascular&#xD;
      smooth muscle cells, leading to coronary, pulmonary, and peripheral vasodilation and&#xD;
      antiinflammatory, antioxidative, antiapoptotic, anti-stunning and cardioprotective effects.&#xD;
      Additionally, Levosimendan which has a long lasting action (up to 7-9 d), resulting from the&#xD;
      formation of active metabolite, may be used as a single 24h perfusion.&#xD;
&#xD;
      In recent preliminary studies, the drug was associated with accelerated weaning from VA-ECMO&#xD;
      and even improved survival. Therefore, a multicenter randomized trial with sufficient&#xD;
      statistical power is needed in refractory cardiogenic shock patients supported by VA-ECMO to&#xD;
      test if the early administration of Levosimendan can facilitate and accelerate VA-ECMO&#xD;
      weaning, and ultimately translate in significantly less morbidity, reduced ICU and hospital&#xD;
      length of stays and associated costs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to successful ECMO weaning within the 30 days following randomization</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 30, Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of ECMO support</measure>
    <time_frame>Between inclusion and Day 30/Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ECMO-free days</measure>
    <time_frame>Between inclusion and Day 30/Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>Between inclusion and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization stay</measure>
    <time_frame>Between inclusion and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Day 30, Day 60</time_frame>
    <description>defined as death, cardiac transplant, escalation to permanent left ventricular assist device, stroke, dialysis, re-hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in hemodynamic parameters</measure>
    <time_frame>Between inclusion and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hemodynamic stabilization</measure>
    <time_frame>Between inclusion and Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with organ failure asessed by sequential organ failure assessment</measure>
    <time_frame>Between inclusion and Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hemodynamic support with catecholamines</measure>
    <time_frame>Between inclusion and Day 30/Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive without hemodynamic support</measure>
    <time_frame>Between inclusion and Day 30/Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Between inclusion and Day 30/Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive without mechanical ventilation</measure>
    <time_frame>Between inclusion and Day 30/Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function assessed with echocardiography</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions</measure>
    <time_frame>Between inclusion and Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A continuous infusion of Levosimendan will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A continuous infusion of Placebo will be administered over 24 h, with no initial bolus. The starting infusion rate will be 0.15 µg/kg/min and will be increased to 0.20 µg/kg/min after 2 hours in the absence of rate-limiting side effects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>A continuous infusion of Levosimendan over 24h</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Levosimendan</intervention_name>
    <description>A continuous infusion of Placebo of Levosimendan over 24h</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute cardiogenic shock patient refractory to conventional therapy placed on VA-ECMO&#xD;
             support in the preceding 48h.&#xD;
&#xD;
             (The rationale for the early use of levosimendan after VA-ECMO initiation appears&#xD;
             strong in patients with refractory cardiogenic shock related to conditions such as&#xD;
             acute myocardial infarction, myocarditis, post-cardiac surgery or post-cardiac arrest.&#xD;
             Myocardial injuries in these situations share many common pathophysiological features,&#xD;
             including ischemia, inflammation and increased oxidative stress leading to extensive&#xD;
             myocardial stunning and dysfunction [26-28]. Besides its inotropic properties that&#xD;
             might quickly improve myocardial contractility, levosimendan might also exert&#xD;
             beneficial antiinflammatory, antioxidative, antiapoptotic, cardioprotective and&#xD;
             anti-stunning effects [29-35] that might accelerate cardiac recovery allowing earlier&#xD;
             weaning from the support).&#xD;
&#xD;
          2. Obtain informed consent from a close relative or surrogate. According to the&#xD;
             specifications of emergency consent, randomization without the close relative or&#xD;
             surrogate consent could be performed.&#xD;
&#xD;
        Close relative/surrogate/family consent will be asked as soon as possible. The patient will&#xD;
        be asked to give his/her consent for the continuation of the trial when his/her condition&#xD;
        will allow.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18&#xD;
&#xD;
          2. Pregnant or lactating womency&#xD;
&#xD;
          3. Initiation of ECMO &gt;48 h&#xD;
&#xD;
          4. Resuscitation &gt;30 minutes before ECMO&#xD;
&#xD;
          5. Irreversible neurological pathology&#xD;
&#xD;
          6. End-stage cardiomyopathy with no hope of LV function recovery&#xD;
&#xD;
          7. Mechanical complication of myocardial infarction&#xD;
&#xD;
          8. Aortic regurgitation &gt; II&#xD;
&#xD;
          9. VA-ECMO for pulmonary embolism&#xD;
&#xD;
         10. VA-ECMO for cardiotoxic drug intoxication&#xD;
&#xD;
         11. VA-ECMO after left-ventricle assist device implantation&#xD;
&#xD;
         12. VA-ECMO in heart transplant patients&#xD;
&#xD;
         13. Patient moribund on the day of randomization, SAPS II &gt;90&#xD;
&#xD;
         14. Liver cirrhosis (Child B or C) and other severe hepatic insufficiency&#xD;
&#xD;
         15. Chronic renal failure requiring hemodialysis&#xD;
&#xD;
         16. Known hypersensitivity to levosimendan&#xD;
&#xD;
         17. Prior history of &quot;torsades de pointes&quot;&#xD;
&#xD;
         18. History of epilepsy&#xD;
&#xD;
         19. Individuals under guardianship, or permanently legally incompetent adults&#xD;
&#xD;
         20. Participation to another interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alain COMBES, MD</last_name>
    <phone>+33142163818</phone>
    <email>alain.combes@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital du Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <state>Bordeaux</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre OUATTARA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain COMBES, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard CHOLLEY, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEVOSIMENDAN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

